# NCT04449874 (NCT04449874)

> A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04449874
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Genentech, Inc.
- Conditions: Non-Small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumors
- Interventions: GDC-6036; Atezolizumab; Cetuximab; Bevacizumab; Erlotinib; GDC-1971; Inavolisib
- Enrollment: 498
- Primary outcome: Percentage of Participants With Adverse Events (AEs)
- Primary outcome: Percentage of Participants With Dose-Limiting Toxicities (DLTs)

## Indexed commentary on NCT04449874 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04449874
